The Latest in the Hepatitis B Drug Pipeline
October 8, 2019
Why cost and treatment length are some of the biggest concerns for drug manufacturers.
Specialty Medications
The Biggest Ways to Reduce Specialty Drug Costs
June 4, 2019
Managed Healthcare Executive’s Managed Care Pharmacy Survey identifies different ways specialty pharmacy stakeholders believe they can reduce industry costs moving forward.
How Payers Are Keeping Specialty Drug Costs Down
April 11, 2019
The real-world strategies used to manage the high cost of specialty meds.
Specialty Pharma Pipeline: 5 Things Health Execs Should Know
October 24, 2018
Specialty pharmaceuticals make up a huge part of the current drug market, and their impact is only going to grow over the next few years.
How the Specialty Pharmaceutical Market is Changing
September 25, 2018
How would you define a specialty pharmaceutical? Chances are, it’s different from the way another healthcare executive would define them.
Right to Try Pros and Cons
June 2, 2018
Legislation removes FDA involvement when patients seek experimental medications. Here’s what critics and proponents say.
Payers struggle to keep up with high rate of FDA drug approvals
October 20, 2017
FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
Meeting the ‘status quo’ with CMS Star Ratings equals regression
October 19, 2017
CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.
Payers can predict budget implications of high-cost drugs in the pipeline
October 19, 2017
A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.
Payers need access to pre-approval drug information
October 19, 2017
Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?
